77 related articles for article (PubMed ID: 6734001)
1. Norethisterone acetate in the treatment of advanced breast cancer.
Earl HM; Rubens RD; Knight RK; Hayward JL
Clin Oncol; 1984 Jun; 10(2):103-9. PubMed ID: 6734001
[TBL] [Abstract][Full Text] [Related]
2. [Oral gestagen treatment of advanced breast neoplasms with norethisterone acetate].
Varini M; Tancini G; Mauri M; Bonadonna G
Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1070-3. PubMed ID: 7423152
[TBL] [Abstract][Full Text] [Related]
3. Aminoglutethimide in the treatment of metastatic breast cancer.
Troner MB
Cancer Res; 1982 Aug; 42(8 Suppl):3402s-3404s. PubMed ID: 7083206
[TBL] [Abstract][Full Text] [Related]
4. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
7. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trial of high-dose medroxyprogesterone acetate in advanced breast cancer].
Jiang Z; Song S; Li J
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):71-3. PubMed ID: 7656795
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
12. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Harris AL; Powles TJ; Smith IE
Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
[TBL] [Abstract][Full Text] [Related]
13. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
14. [Experience in the treatment of metastatic breast carcinoma with norethisterone acetate in a clinical study].
Stier G; Gürtler R; Schmidt UM
Arch Geschwulstforsch; 1989; 59(2):93-8. PubMed ID: 2655553
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study.
Johnson PA; Bonomi PD; Anderson KM; Wolter JM; Bacon LD; Rossof AH; Economou SG
Cancer Treat Rep; 1983; 67(7-8):717-20. PubMed ID: 6871887
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
18. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma.
Jain V; Landry M; Levine EA
Am Surg; 1996 Feb; 62(2):162-5. PubMed ID: 8554195
[TBL] [Abstract][Full Text] [Related]
19. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
[TBL] [Abstract][Full Text] [Related]
20. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Lavrenkov K; Man S; Geffen DB; Cohen Y
Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]